Network pharmacology-based therapeutic intervention of Mentha arvensis targeting cancer and doxorubicin-induced cardiotoxicity - PubMed
12 hours ago
- #Network Pharmacology
- #Mentha arvensis
- #Doxorubicin Cardiotoxicity
- Doxorubicin (Dox) is effective against various cancers but causes dose-dependent cardiotoxicity (DIC).
- Dexrazoxane (Dexa) is the only FDA-approved cardioprotective agent but compromises Dox's anticancer effects and poses risks like secondary malignancies.
- A network pharmacology approach screened 39 phytochemicals from Mentha arvensis for potential dual-action agents against DIC and cancer.
- Key phytochemicals like Citronellol showed promise in combination with Dexa, preserving Dox's anticancer efficacy and Dexa's cardioprotection.
- Common targets for cancer and DIC included TNFA, MMP2, PTGS2, JUN, and HMOX1 when using M. arvensis phytochemicals alone.
- Combining phytochemicals with Dexa identified shared targets like TNFA, ACE, SIRT1, CDK2, and AKR1B1.
- Mentha arvensis phytochemicals may mitigate DIC while maintaining anticancer activity, but experimental validation is needed.
- Future studies should explore combinatorial strategies in vivo to confirm efficacy and elucidate molecular mechanisms.